<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029778</url>
  </required_header>
  <id_info>
    <org_study_id>097/20</org_study_id>
    <nct_id>NCT05029778</nct_id>
  </id_info>
  <brief_title>Arginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth Curve</brief_title>
  <official_title>Efficacy L-arginine + L-citrulline as a Dietary Supplement vs Placebo for Weight Gain in Fetus With a Decrease in Their Growth Curve in the Third Trimester of Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Civil de Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Civil de Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction:&#xD;
&#xD;
      The high incidence of intrauterine growth restriction is a public health problem; in this&#xD;
      pathology, newborns present weight below the 10th percentile, this implies an increase in&#xD;
      morbidity in the short term (complications due to hypoxia) and long term (pathologies typical&#xD;
      of Fetal Programming) as well as the cost of health services. L-arginine at different doses&#xD;
      has been used for some pathologies such as preeclampsia with controversial results. Authors&#xD;
      have mentioned that the joint administration of l-citrulline can increase the efficacy of&#xD;
      l-arginine. A stunted fetus is a challenge for the fetal physician; due to the complexity of&#xD;
      the follow-up, but above all to determine the moment for the termination of the pregnancy.&#xD;
      Finding some treatment to promote weight gain would improve the short- and long-term&#xD;
      expectations of these infants.&#xD;
&#xD;
      General objective To determine the efficacy of L-arginine + L-Citrulline (3 / 2g) every 24&#xD;
      hours, in fetuses with a decrease in their growth curve in the third trimester of pregnancy.&#xD;
&#xD;
      Material and methods Clinical trial, parallel, controlled, randomized simple, Double blind.&#xD;
      Two groups of pregnant women will be carried out in the third trimester; fetus with a&#xD;
      decrease in its growth curve, percentile&gt; 10 and &lt;25 for gestation age, they will be given an&#xD;
      informed consent letter and they will be randomized (double blind), they will proceed to give&#xD;
      intervention (L-arginine + Citrin (3 / 2 g) every 24 hours Vs placebo), a follow-up will be&#xD;
      carried out every two weeks, where the weight and growth curve will be calculated in&#xD;
      percentile, until the resolution of the pregnancy and data will be taken from the perinatal&#xD;
      results in both groups.&#xD;
&#xD;
      Statistic analysis Medics of central tendency will be calculated and Chi squared will be&#xD;
      applied for qualitative variables, T of student for qualitative variables and it is&#xD;
      considered P &lt;0.005.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 patients with a pregnancy of more than 26 weeks of gestation, 25 with intervention and 25&#xD;
      control will be included; in which the fetus is between 10 and 25th percentile . It will be&#xD;
      carried out in the obstetric service of the old civil hospital, with a double-blind&#xD;
      randomization.&#xD;
&#xD;
      Evaluations will be carried out every two weeks where the fetal weight, umbilical artery&#xD;
      Doppler, middle cerebral artery, venous duct, uterine arteries, amniotic fluid, placenta will&#xD;
      be evaluated.&#xD;
&#xD;
      The assessment will be made until birth, from where the birth weight, height, Apgar, Capurro&#xD;
      score, characteristics and placental weight, approximate bleeding will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2021</start_date>
  <completion_date type="Anticipated">January 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Clinical Trial open controlled parallel randomized simple</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>we donÂ´t know who receives the intervention and who receives the placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal Growth</measure>
    <time_frame>10 weeks</time_frame>
    <description>fetal weight gain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Fetal Growth Retardation</condition>
  <arm_group>
    <arm_group_label>Experimental L-arginine 3 g and L-citruline 2 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: L-arginine 3g and L-citruline 2g, Food supplement, PO , for 24 h, until birth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo 3g ( starch ) PO for 24 h. until birth</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-arginine 3g + L-Citruline 2 g</intervention_name>
    <description>receive L-arginine 3g + l-Citruline 2 g PO, for 24 h, until birth.</description>
    <arm_group_label>Experimental L-arginine 3 g and L-citruline 2 g</arm_group_label>
    <other_name>L-arginine 3g</other_name>
    <other_name>L-Citruline 2 g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>receive placebo 3g PO, for 24 h, until birth.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnancy with a single fetus&#xD;
&#xD;
          -  Patient over 18 years of age&#xD;
&#xD;
          -  Patient under 35 years of age&#xD;
&#xD;
          -  Pregnancy greater than 25 weeks' gestation confirmed by first trimester ultrasound or&#xD;
             reliable last period&#xD;
&#xD;
          -  Fetus with decrease or flattening of its growth curve by ultrasound (P&gt; 10 and &lt;25)&#xD;
&#xD;
          -  Apparently healthy fetus&#xD;
&#xD;
          -  Fetus without Doppler alterations in any of its blood vessels (Venous Ductus, Cerebral&#xD;
             Artery medial, Umbilical Artery .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fetus diagnosed with a malformation&#xD;
&#xD;
          -  Fetus diagnosed with a syndrome or chromosomopathy&#xD;
&#xD;
          -  Fetus below the 10th percentile for gestational age by ultrasound&#xD;
&#xD;
          -  Mother with Type 1, Type 2 or Gestational Diabetes mellitus.&#xD;
&#xD;
          -  Chronic maternal hypertension&#xD;
&#xD;
          -  Preeclampsia with data of severity or early onset&#xD;
&#xD;
          -  Aspirin intake (100-150 mg a day from the first trimester of pregnancy)&#xD;
&#xD;
          -  Fetus with a poor ultrasonographic window for evaluation.&#xD;
&#xD;
          -  Mother with BMI &lt;18.5 prior to pregnancy&#xD;
&#xD;
          -  Maternal BMI&gt; 30&#xD;
&#xD;
          -  Known allergy to treatment&#xD;
&#xD;
          -  Non-reassuring fetal state.&#xD;
&#xD;
          -  Abnormal placental insertion.&#xD;
&#xD;
          -  Patient with renal insufficiency, LUPUS or Antiphospholipid syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>single pregnancy in third trimester with fetus between the 10th to 25th percentile</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milton Omar Guzman Ornelas, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge Bravo Rubio, Dr</last_name>
    <phone>3221186759</phone>
    <email>naranjo125@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Campechano Ascencio, Dra</last_name>
    <phone>3310233983</phone>
    <email>angelescampechano@hotmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Dover GJ. The Barker hypothesis: how pediatricans will diagnose and prevent common adult-onset diseases. Trans Am Clin Climatol Assoc. 2009;120:199-207. Review.</citation>
    <PMID>19768178</PMID>
  </reference>
  <results_reference>
    <citation>Ananth CV, Vintzileos AM. Distinguishing pathological from constitutional small for gestational age births in population-based studies. Early Hum Dev. 2009 Oct;85(10):653-8. doi: 10.1016/j.earlhumdev.2009.09.004. Epub 2009 Sep 27.</citation>
    <PMID>19786331</PMID>
  </results_reference>
  <results_reference>
    <citation>Barker DJ, Osmond C, Kajantie E, Eriksson JG. Growth and chronic disease: findings in the Helsinki Birth Cohort. Ann Hum Biol. 2009 Sep-Oct;36(5):445-58. doi: 10.1080/03014460902980295.</citation>
    <PMID>19562567</PMID>
  </results_reference>
  <results_reference>
    <citation>Bourdon A, Parnet P, Nowak C, Tran NT, Winer N, Darmaun D. L-Citrulline Supplementation Enhances Fetal Growth and Protein Synthesis in Rats with Intrauterine Growth Restriction. J Nutr. 2016 Mar;146(3):532-41. doi: 10.3945/jn.115.221267. Epub 2016 Feb 10.</citation>
    <PMID>26865647</PMID>
  </results_reference>
  <results_reference>
    <citation>Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, GiguÃ¨re Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2009 Sep;31(9):818-826. doi: 10.1016/S1701-2163(16)34300-6. Review.</citation>
    <PMID>19941706</PMID>
  </results_reference>
  <results_reference>
    <citation>Byrne BM, Howard RB, Morrow RJ, Whiteley KJ, Adamson SL. Role of the L-arginine nitric oxide pathway in hypoxic fetoplacental vasoconstriction. Placenta. 1997 Nov;18(8):627-34.</citation>
    <PMID>9364597</PMID>
  </results_reference>
  <results_reference>
    <citation>Camarena Pulido EE, GarcÃ­a Benavides L, Panduro BarÃ³n JG, Pascoe Gonzalez S, Madrigal Saray AJ, GarcÃ­a Padilla FE, Totsuka Sutto SE. Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: A double-blind, randomized, clinical trial. Hypertens Pregnancy. 2016 May;35(2):217-25. doi: 10.3109/10641955.2015.1137586. Epub 2016 Mar 22.</citation>
    <PMID>27003763</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen J, Gong X, Chen P, Luo K, Zhang X. Effect of L-arginine and sildenafil citrate on intrauterine growth restriction fetuses: a meta-analysis. BMC Pregnancy Childbirth. 2016 Aug 16;16:225. doi: 10.1186/s12884-016-1009-6. Review.</citation>
    <PMID>27528012</PMID>
  </results_reference>
  <results_reference>
    <citation>Colella M, FrÃ©rot A, Novais ARB, Baud O. Neonatal and Long-Term Consequences of Fetal Growth Restriction. Curr Pediatr Rev. 2018;14(4):212-218. doi: 10.2174/1573396314666180712114531. Review.</citation>
    <PMID>29998808</PMID>
  </results_reference>
  <results_reference>
    <citation>Cottrell E, Tropea T, Ormesher L, Greenwood S, Wareing M, Johnstone E, Myers J, Sibley C. Dietary interventions for fetal growth restriction - therapeutic potential of dietary nitrate supplementation in pregnancy. J Physiol. 2017 Aug 1;595(15):5095-5102. doi: 10.1113/JP273331. Epub 2017 Feb 27. Review.</citation>
    <PMID>28090634</PMID>
  </results_reference>
  <results_reference>
    <citation>Crispi F, Miranda J, GratacÃ³s E. Long-term cardiovascular consequences of fetal growth restriction: biology, clinical implications, and opportunities for prevention of adult disease. Am J Obstet Gynecol. 2018 Feb;218(2S):S869-S879. doi: 10.1016/j.ajog.2017.12.012. Review.</citation>
    <PMID>29422215</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Civil de Guadalajara</investigator_affiliation>
    <investigator_full_name>Jorge Bravo Rubio</investigator_full_name>
    <investigator_title>Fetal and maternal medicine</investigator_title>
  </responsible_party>
  <keyword>L-arginine, l-Citruline, Fetal growth, percentile,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

